Drug Plan Trends Report: A snapshot of what’s coming down the pike
The hepatitis C hump is over. Since 2014, Health Canada has approved several promising medications for the disease. While the direct-acting antivirals offer cure rates of more than 90 per cent, they cost tens of thousands of dollars, and benefits plans felt the pinch. But now, “after an initial spike in treatment requests, claims have […]
- March 16, 2018 March 17, 2021
- 08:56